Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Leveljump HealthcareJMPHF EV-to-EBIT is -34.82 as of Jul. 29, 2026. The stock has 1 warning sign investors should review. Among 104 Medical Diagnostics & Research companies, Leveljump Healthcare ranks better than 64.42% on this metric.
The historical rank and industry rank for Leveljump Healthcare's EV-to-EBIT or its related term are showing as below:
JMPHF'
s EV-to-EBIT Range Over the Past 10 Years
Min: -40.13 Med: -4.27 Max: 258.1
Current: -35.78
During the past 7 years, the highest EV-to-EBIT of Leveljump Healthcare was 258.10. The lowest was -40.13. And the median was -4.27.
JMPHF's EV-to-EBIT is ranked better than 64.42% of 104
companies
in the Medical Diagnostics & Research industry
Industry Median: 23.365
vs JMPHF: -35.78
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Leveljump Healthcare's Enterprise Value for the quarter that ended in Mar. 2026 was $10.69 Mil.
Leveljump Healthcare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leveljump Healthcare EV-to-EBIT Related Terms
Leveljump Healthcare EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Leveljump Healthcare's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Leveljump Healthcare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Leveljump Healthcare EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Leveljump Healthcare's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Leveljump Healthcare's EV-to-EBIT falls into.
Leveljump Healthcare's current Enterprise Value is $10.69 Mil.
Leveljump Healthcare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Leveljump Healthcare (JMPHF) has a EV-to-EBIT of -34.82 as of Jul. 29, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Leveljump Healthcare and its competitors. According to the industry distribution chart, Leveljump Healthcare ranks #37 out of 104 companies in the Medical Diagnostics & Research industry, placing it in the top 35.6%.
Is Leveljump Healthcare's EV-to-EBIT too high?
Leveljump Healthcare's current EV-to-EBIT is -34.82. Based on the distribution chart, Leveljump Healthcare ranks #37 out of 104 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint.
How does Leveljump Healthcare's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Leveljump Healthcare ranks #37 out of 104 companies for EV-to-EBIT. This puts Leveljump Healthcare in the upper half of its industry. The industry median EV-to-EBIT is 23.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.37, based on 104 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Leveljump Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Leveljump Healthcare's current EV-to-EBIT is -34.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Leveljump Healthcare stock overvalued right now?
Leveljump Healthcare (JMPHF) has a current EV-to-EBIT of -34.82. The stock's GF Value™ is $0.05, compared to a current price of $0.04 — trading 14.5% below its estimated fair value. The current EV-to-EBIT is -34.82. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Leveljump Healthcare (JMPHF), the current EV-to-EBIT is -34.82 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Leveljump Healthcare Corp is engaged in providing radiology services both by providing direct patient images and by providing Teleradiology services, which is the process of providing remote off-site reading of radiology scans such as CT, MRI, and X-ray. Its teleradiology services allow hospital staff to scan their emergency room patients, then page the company's radiologist on call, who can then remotely view, via a secured server, the images and diagnose the patient, and provide a report back to the hospital. Leveljump provides its direct-to-patient services at its Independent Healthcare Facilities (IHFs). The company operates as a single segment, with all of its core assets, intellectual property, and development work being conducted in Canada.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JMPHF has been successfully added to your 
